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EDITORIAL
Management  of  lung  nodules  in  2013Our  understanding  of  the  morphological  features  and  natural  history  of  both  benign
lung  nodules  and  small  lung  cancers  has  improved  as  a  result  of  all  of  the  observational
prospective  and  randomized  studies  on  the  annual  use  of  low  dose  chest  CT  for  early
screening  of  lung  cancer  in  at  risk  people  (mostly  smokers  over  50  years  old).  Reports  of
these  ﬁndings  have  been  published  over  the  last  ﬁfteen  or  so  years  and  have  led  to  the
construction  of  international  multidisciplinary  consensus  guidelines  on  the  management  of
undeﬁned  lung  nodules,  which  both  reduce  the  number  of  monitoring  CTs  but  at  the  same
time  avoid  leaving  a  wholly  operable  lung  cancer  to  progress  [1—3].  It  has  been  shown,  for
example,  that  a  solid  nodule  with  smooth  outlines  which  is  oval,  lenticular  or  triangular  in
shape,  is  located  in  contact  with  a  scissure,  and  is  between  2.8  and  10.6  mm  in  size  (aver-
age:  4.4  mm)  is  invariably  not  malignant  and  represents  an  intrapulmonary  lymph  node,
even  if  it  increases  in  size  on  repeat  investigations  and  sometimes  has  a  volume  doubling
time  of  under  400  days  [4].  Conversely,  it  has  now  been  fully  recognized  that  a  low-density
ground  glass  nodule  (5—20  mm  in  diameter)  can  remain  completely  stable  for  several
months  or  years  even  though  it  represents  a  non-  or  poorly  invasive  adenocarcinoma  [5].
An  excellent  review  of  current  knowledge  by  Lederlin  et  al.  on  the  natural  history  of
small  primary  lung  adenocarcinomas  and  the  role  of  imaging  to  identify  and  deﬁne  these
is  particularly  welcomed  in  this  edition  [6]. The  authors  recall  the  rationale  for  the  new
international  histological  classiﬁcation  of  primary  lung  adenocarcinomas,  which  is  based  on
the  natural  history  and  prognostic  ﬁndings,  supported  by  anatomic-radiologic  correlations
[7].  They  then  summarize  the  results  of  the  North  American  randomized  study  (NLST),
which  assesses  the  impact  of  early  screening  with  annually  repeated  low  dose  chest  CT
screening  on  lung  cancer  mortality  in  at  risk  patients  [8]. Finally,  they  provide  a  full  analysis
of  the  remaining  uncertainties,  which  currently  limit  the  appropriateness  of  implementing
any  organized  screening  process  for  lung  cancer  using  annual  low  dose  CT.
The  authors  also  review  the  management  strategy  for  lung  nodules  and  emphasize  the
importance  of  nodule  volumetry  which  provides  for  more  accurate  measurements  (repro-
ducibility)  than  merely  nodule  diameter  and  enables  the  nodule  volume  doubling  time  to
be  calculated  in  the  ﬁrst  follow-up  scan  [9,10]. Using  the  algorithm  developed  in  the  NEL-
SON  study,  the  authors  recommend  that  all  solid  nodules  with  a  volume  doubling  time  of
400  days  or  more  on  the  ﬁrst  review  at  3  months  should  be  considered  to  be  benign  [11].
Because  of  this,  a  single  one  year  review  conﬁrming  stability  of  the  lesion  would  appear  to
be  sufﬁcient  to  deﬁnitively  conﬁrm  that  it  is  benign  and  reduce  the  number  of  CT  repeats
which  were  previously  required  in  the  Fleischner  Society  guidelines  published  in  2005  [1].
The  authors  suggest  a  conservative  approach  to  partially  solid  nodules  based  on  annual
follow-up  for  3  to  5  years  when  the  solid  component  is  less  than  5  mm  in  size  as  these
lesions  histologically  represent  mini-invasive  adenocarcinomas.
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Lederlin  et  al.  also  highlight  the  importance  of  the  multi-
isciplinary  team  meeting  for  the  management  of  nodules,
hich  are  very  strongly  suspected  to  be  malignant  from
T  [6].  The  decision  as  to  whether  or  not  to  perform  a
ransbronchial  or  transthoracic  biopsy  or  positron  emission
omography  and  the  choice  of  optimal  treatment  (lobec-
omy  followed  by  mediastinal  lymph  node  clearance  for
 conﬁrmed  adenocarcinoma  compared  to  segmentectomy,
edge  resection  or  sub-segmentectomy  for  a  non-solid  nod-
le)  is  taken  in  this  meeting.
Despite  all  of  the  knowledge  which  has  been  gained  which
as  optimized  the  management  of  nodules,  summarized
xcellently  in  the  article  by  Lederlin  et  al.  [6],  a  number
f  uncertainties  remain:  do  lesions  of  atypical  adenomatous
yperplasia  and  in  situ  adenocarcinomas  transform  into
nvasive  adenocarcinomas?  Does  this  type  of  single  lesion
rogress  to  multiple  lesions?  What  is  the  role  of  biomarkers
n  identifying  invasive  adenocarcinomas?  What  would  be  the
mpact  of  measuring  the  solid  and  non-solid  components  of
artially  solid  nodules  in  future  revisions  of  the  TNM  classi-
cation  to  assess  lung  cancers?
There  is  also  undoubtedly  a  clear  need  to  develop  reliable
uantitative  methods  to  monitor  non-solid  and  partially  solid
odules.
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